New hope: expanded access to cemiplimab for cancer patients

This program provides expanded access to cemiplimab, an immunotherapy drug, for patients with certain solid tumors including non-small cell lung cancer, basal cell carcinoma, and cutaneous squamous cell carcinoma. The goal is to make the treatment available to those who may not have other options. Participants receive cemiplimab under a compassionate use framework.